Sonnet BioTherapeutics Holdings, Inc. (SONN) Research
Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This innovative system employs human single-chain antibody fragments specifically engineered to bind to human serum albumin, leveraging it for enhanced delivery and transport to target tissues. Their leading therapeutic candidate, SON-1010, is a fully human variant of interleukin 12, currently being advanced for the treatment of non-small cell lung cancer and cancers affecting the head and neck. Additionally, Sonnet is progressing SON-080, another fully human interleukin 6 formulation, intended to address both chemotherapy-induced and diabetic peripheral neuropathy. The company also maintains a licensing agreement with New Life Therapeutics PTE, LTD., for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.
Market snapshot
- Symbol
- SONN
- Price
- $1.26
- Day change
- -59.35%
- Market cap
- $8.4M
- P/E ratio
- -0.32x
- 52-week range
- 1.08-19.3
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- Kenney Richard T — M-Exempt (163760 shares) on 2025-12-02
- Kenney Richard T — M-Exempt (86505 shares) on 2025-12-02
- Kenney Richard T — F-InKind (16891 shares) on 2025-12-02
- Kenney Richard T — M-Exempt (86505 shares) on 2025-12-02
- Kenney Richard T — D-Return (69614 shares) on 2025-12-02
Open Sonnet BioTherapeutics Holdings, Inc. (SONN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.